Myopia Treatment Market Report 2026

The myopia treatment market size has grown strongly in recent years. It will grow from $19.52 billion in 2025 to $21.38 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing screen time exposure, rise in childhood myopia prevalence, limited access to preventive eye care, early development of refractive surgery techniques, initial adoption of corrective eyewear solutions.

The myopia treatment market size is expected to see strong growth in the next few years. It will grow to $30.38 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to growing awareness of myopia control therapies, expansion of laser treatment technologies, rising demand for orthokeratology, increasing investment in ophthalmic research, adoption of advanced diagnostic tools. Major trends in the forecast period include rising adoption of orthokeratology (ortho-k), increasing preference for minimally invasive refractive surgeries, growing demand for myopia control lenses in children, higher prevalence of digital eye strain-driven myopia, expansion of preventive eye care awareness programs.

The rising increase in screen time is expected to drive the growth of the myopia treatment market going forward. Screen time refers to the duration a person spends using devices with screens, including smartphones, tablets, computers, and televisions. Factors such as the growth of streaming services, social media, remote work, and virtual meetings have contributed to higher screen time. Myopia treatment helps alleviate eye strain and discomfort from prolonged screen exposure, improving focus, visual comfort, and clarity. For instance, in October 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that between July 2021 and December 2023, 50.4% of teenagers aged 12-17 spent four or more hours per day on screens, 22.8% spent three hours, 17.8% spent two hours, 6.1% spent one hour, and 3% spent less than one hour daily. Therefore, the rise in screen time is driving the growth of the myopia treatment market.

Major companies in the myopia treatment market are focusing on innovative technologies, such as optical biometers, to improve diagnostic accuracy and deliver personalized treatment plans. Optical biometers employ light-based measurements to assess eye parameters like axial length and corneal curvature, critical for diagnosing and monitoring myopia progression. For instance, in February 2023, NIDEK Co., Ltd., a Japan-based ophthalmic product manufacturer, launched the AL-Scan M and MV-1. The AL-Scan M integrates 3D auto-tracking and auto-shot functions, enabling precise axial length measurements and efficient, user-friendly testing, particularly for younger patients. It also pairs with MV-1 Myopia Viewer software to monitor patient behavior and track treatment history effectively.

In January 2023, CooperVision, Inc., a US-based manufacturer of soft contact lenses, acquired SynergEyes, Inc. for an undisclosed amount. This acquisition expands CooperVision’s specialty contact lens portfolio and strengthens its position in advanced ocular care. SynergEyes, Inc. is a US-based company specializing in specialty contact lenses designed to manage myopia progression.

Major companies operating in the myopia treatment market are Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Corporation, Johnson & Johnson Vision Care Inc., CooperVision Inc., Menicon Co. Ltd., Topcon Healthcare Inc., Essilor Ltd., NIDEK CO. LTD., SightGlass Vision Inc., SCHWIND eye-tech-solutions GmbH, Visioneering Technologies Inc., MEDMONT INTERNATIONAL PTY LTD., Vyluma Inc., Haag-Streit Holding AG, NovaSight Ltd., Euclid Vision Corporation, Treehouse Eyes LLC, Sydnexis Inc., Neurobit Technologies Co. Ltd., Kubota Pharmaceutical Holdings Co. Ltd.

Asia Pacific was the largest region in the myopia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myopia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myopia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the myopia treatment market by increasing costs for optical lenses, refractive surgery equipment, and pharmacological formulations sourced internationally. Segments such as contact lenses, LASIK, PRK, and orthokeratology are most affected, especially in Asia-Pacific and Europe where supply chains rely on imported precision optics and medical devices. These added costs have slightly reduced procedure volumes in price-sensitive markets. Conversely, tariffs are driving investments in local lens manufacturing and regional surgical equipment production.

The myopia treatment market research report is one of a series of new reports that provides myopia treatment market statistics, including myopia treatment industry global market size, regional shares, competitors with a myopia treatment market share, detailed myopia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myopia treatment industry. This myopia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myopia treatment refers to medical or corrective interventions aimed at managing or correcting myopia, also known as nearsightedness. Myopia is a common refractive error in which distant objects appear blurry while close objects remain clear. The primary goal of myopia treatment is to improve vision and quality of life by correcting refractive errors, as well as to manage the progression of myopia, reducing long-term dependence on corrective lenses.

The main types of myopia addressed in treatment are simple myopia, high myopia, and pathological myopia. Simple myopia occurs when distant objects appear blurry due to an elongated eyeball or overly curved cornea and can be treated with corrective lenses or refractive surgery. Treatments include eyeglasses, contact lenses, refractive surgery, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and orthokeratology (Ortho-K). Various routes of administration, such as oral, parenteral, and others, are used depending on the therapy. Myopia treatments are distributed through channels including direct tenders, retail sales, and others, and are utilized by end users such as hospitals, clinical laboratories, physician offices, reference laboratories, and more.

The myopia treatment market consists of revenues earned by entities by providing services such as myopia control programs, vision therapy, and lifestyle and behavioral guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The myopia treatment market includes sales of prescription glasses, atropine drops, and myopia control glasses. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.